AI
| Followers | 1734 |
| Posts | 210213 |
| Boards Moderated | 11 |
| Alias Born | 01/02/2008 |
Wednesday, March 09, 2011 7:24:53 PM
ALTH Allos Therapeutics "CHARTS"
Top Stock Picks Under $5 for 2011
http://www.thestreet.com/print/story/10950401.html
Company Profile: Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer. The company's Folotyn (pralatrexate) is designed to treat T-cell lymphoma.
Share Price: $4.35(Dec. 17)
2010 Stock Performance: -34%
Analyst Consensus: Seven analysts say investors should buy shares of Allos Therapeutics. Three other analysts recommend that investors hold shares. No researcher has a "sell" rating on Allos.
Bullish Case: In a Dec. 13 research note, ThinkEquity analyst Brian Skorney said the firm has a "buy" rating and a $10 price target on Allos, noting several new clinical analyses of Folotyn.
"New data in T-cell malignancies show compelling efficacy compared to potential competitors and provides additional rationale for oncologists to adopt Folotyn as an important therapy for patients," Skorney wrote.
ALTH ----- charts
Top Stock Picks Under $5 for 2011
http://www.thestreet.com/print/story/10950401.html
Company Profile: Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer. The company's Folotyn (pralatrexate) is designed to treat T-cell lymphoma.
Share Price: $4.35(Dec. 17)
2010 Stock Performance: -34%
Analyst Consensus: Seven analysts say investors should buy shares of Allos Therapeutics. Three other analysts recommend that investors hold shares. No researcher has a "sell" rating on Allos.
Bullish Case: In a Dec. 13 research note, ThinkEquity analyst Brian Skorney said the firm has a "buy" rating and a $10 price target on Allos, noting several new clinical analyses of Folotyn.
"New data in T-cell malignancies show compelling efficacy compared to potential competitors and provides additional rationale for oncologists to adopt Folotyn as an important therapy for patients," Skorney wrote.
ALTH ----- charts
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
